Research & Technology
Research & Technology
Institut Pasteur Korea (IPK) strives to address global health issues by combining cutting-edge approaches and technology that enable understanding of disease mechanisms and the development of new treatment and prevention strategies.
Discovery Biology Division studies diseases and pathogens, from which researchers establish disease models and assays for drug screening. Additionally, target identification and studies for the mechanism of action (MoA) are conducted for the candidates identified from screening.
Translational Research Division evaluates the drug efficacy of thousands of compounds through the cell- and image-based screening operated in the BSL-2 and BSL-3 laboratories and identifies novel candidates. The identified candidates are further developed to have more drug-like properties by SAR, toxicity and lead optimization studies and their in-vivo efficacy is evaluated in animal experiments.
The IPK Biobank secures, standardizes, and supplies high-risk and emerging infectious disease pathogens and human samples for the research community and contributes to the preparation and timely response to public health crises.
The drug candidates are transferred for subsequent development including (pre-) clinical trials. Institut Pasteur Korea works closely in collaboration with the pharmaceutical industry, bio venture companies, academia and hospitals to enable its research technology and output to be utilized in helping the patients in need.
IPK employs dynamic robotic platforms for high-throughput screening of chemical libraries and RNAi collections. Our fully-automated robotic platforms are located in BSL-2 and BSL-3 laboratories suitable for most pathogens and biological research.